What could be causing continuous fatigue and daytime sedation in a patient taking duloxetine 90 mg daily, aripiprazole (Abilify) 5 mg daily, and buspirone 10 mg twice daily?

Medication-Induced Fatigue and Sedation

The continuous fatigue and daytime sedation in your patient is most likely caused by aripiprazole (Abilify), with a potential contributory effect from the duloxetine-aripiprazole drug interaction that elevates aripiprazole levels. While duloxetine and buspirone can cause somnolence, aripiprazole has the strongest evidence for dose-dependent sedation, particularly when combined with duloxetine.

Primary Culprit: Aripiprazole

Aripiprazole is the most probable cause of your patient's sedation. According to FDA labeling data, somnolence and sedation are among the most common adverse effects of aripiprazole 11. The drug demonstrates a clear dose-response relationship for sedation—in adult schizophrenia trials, somnolence occurred in 7.1% on placebo versus 12.6% at 30mg doses 1. Even at lower doses used for augmentation in depression (2-20mg), sedation occurred in 4% of patients versus 2% on placebo 1.

Importantly, fatigue was reported in 8% of patients on aripiprazole augmentation for major depressive disorder compared to 4% on placebo 1. The FDA label explicitly lists both sedation and somnolence as common adverse reactions across multiple indications 11.

Critical Drug Interaction: Duloxetine Increases Aripiprazole Levels

Your patient's symptoms are likely exacerbated by a significant pharmacokinetic interaction between duloxetine and aripiprazole. A 2023 study demonstrated that duloxetine co-administration increases aripiprazole plasma concentrations by 54.2%, with dose-adjusted concentrations 45.6% higher than monotherapy 2. This occurs through duloxetine's inhibition of CYP2D6 (the primary metabolic pathway for aripiprazole) and to a lesser extent CYP3A4 2.

The interaction is dose-dependent—higher duloxetine doses (your patient is on 90mg, which is above the standard 60mg) correlate with higher aripiprazole levels 2. This means your patient is effectively receiving a higher aripiprazole dose than prescribed, increasing sedation risk.

Contributing Factors

Duloxetine

While duloxetine can cause somnolence, the 2020 AACAP guidelines note this as a recognized adverse effect but not typically the predominant one 33. A 2012 naturalistic study found drowsiness in only 15% of patients on duloxetine, and it was generally mild 4. However, at 90mg daily (above the standard 60mg dose), your patient may experience more pronounced effects.

Buspirone

Buspirone at 10mg BID is unlikely to be the primary cause. The 2002 Alzheimer's guidelines note buspirone may take 2-4 weeks to become effective and is generally well-tolerated 5. A 2020 study showed buspirone augmentation did not significantly increase sedation in depression patients 6.

Diagnostic Approach

Evaluate these specific factors:

• Timing: When did fatigue begin relative to medication initiation/dose changes? Aripiprazole-induced sedation can have a biphasic pattern—one case report documented initial lethargy with brief improvement followed by subsequent decline 7
• Sleep architecture: Rule out aripiprazole-induced sleep apnea from weight gain (aripiprazole causes weight gain in 3% of patients) 1
• Anticholinergic burden: While aripiprazole has lower anticholinergic activity than some antipsychotics, combined with duloxetine it may contribute to cognitive slowing 8
• Metabolic factors: Check thyroid function and HbA1c—aripiprazole can cause metabolic changes that indirectly worsen fatigue 1

Management Algorithm

Step 1: Reduce Aripiprazole Dose

• Given the drug interaction elevating aripiprazole levels by ~50%, consider reducing aripiprazole to 2.5mg daily
• Monitor for 2-4 weeks for improvement in sedation while maintaining therapeutic benefit for depression

Step 2: If Sedation Persists

• Consider switching aripiprazole to a less sedating augmentation strategy
• Alternatives include cariprazine (lower metabolic burden) or brexpiprazole (though still may cause sedation)
• Alternatively, optimize duloxetine alone by reducing to 60mg daily (standard dose) to decrease the interaction effect

Step 3: Timing Optimization

• Administer aripiprazole at bedtime rather than morning to leverage sedation for sleep
• Ensure duloxetine is given in morning to minimize evening sedation overlap

Step 4: If Refractory

• Consider discontinuing aripiprazole entirely and trying non-pharmacologic augmentation (cognitive behavioral therapy)
• Or switch to a different augmentation class entirely (e.g., thyroid hormone, lithium)

Critical Pitfalls to Avoid

• Don't assume all three medications contribute equally—the evidence strongly implicates aripiprazole, especially given the duloxetine interaction
• Don't increase stimulants to counteract sedation without first addressing the root cause—this creates polypharmacy complications
• Don't abruptly discontinue aripiprazole—taper over 1-2 weeks to avoid withdrawal symptoms
• Don't ignore the dose-dependent nature of the duloxetine-aripiprazole interaction—even small aripiprazole dose reductions may significantly improve symptoms given the elevated plasma levels

The evidence clearly points to aripiprazole as the primary culprit, amplified by duloxetine's metabolic inhibition creating supra-therapeutic aripiprazole levels.